<div id="readability-page-1"><p>Carnegie Lake Advisors LLC acquired a new stake in shares of  RxSight, Inc. (NASDAQ:RXST - Free Report) in the second quarter, according to the company in its most recent Form 13F filing with the Securities &amp; Exchange Commission. The firm acquired 107,000 shares of the company's stock, valued at approximately $1,391,000. Carnegie Lake Advisors LLC owned about 0.26% of RxSight at the end of the most recent quarter.</p><p>Other hedge funds have also recently added to or reduced their stakes in the company. Bank of New York Mellon Corp lifted its stake in  RxSight by 0.8% in the first quarter. Bank of New York Mellon Corp now owns 103,659 shares of the company's stock valued at $2,617,000 after acquiring an additional 777 shares during the last quarter.  Grant GrossMendelsohn LLC raised its holdings in shares of  RxSight by 129.0% during the 1st quarter. Grant GrossMendelsohn LLC now owns 16,618 shares of the company's stock valued at $420,000 after purchasing an additional 9,360 shares in the last quarter.  New York State Common Retirement Fund raised its holdings in shares of  RxSight by 38.4% during the 1st quarter. New York State Common Retirement Fund now owns 407,035 shares of the company's stock valued at $10,278,000 after purchasing an additional 112,984 shares in the last quarter.  Victory Capital Management Inc. raised its holdings in shares of  RxSight by 3.6% during the 1st quarter. Victory Capital Management Inc. now owns 281,658 shares of the company's stock valued at $7,112,000 after purchasing an additional 9,680 shares in the last quarter.  Finally, Tempus Wealth Planning LLC acquired a new stake in shares of  RxSight in the 1st quarter valued at $272,000. Institutional investors and hedge funds own  78.78% of the company's stock. </p><h2>RxSight Stock Up 3.2%</h2><p>RXST opened at $8.61 on Friday. The stock's 50 day moving average price is $8.78 and its two-hundred day moving average price is $10.81. The firm has a market capitalization of $352.32 million, a P/E ratio of -9.78 and a beta of 1.16. RxSight, Inc. has a 12-month low of $6.32 and a 12-month high of $55.57. </p><p>RxSight (NASDAQ:RXST - Get Free Report) last issued its quarterly earnings results on Wednesday, November 5th. The company reported ($0.04) EPS for the quarter, topping analysts' consensus estimates of ($0.19) by $0.15. RxSight had a negative return on equity of 12.78% and a negative net margin of 25.15%.The company had revenue of $30.34 million during the quarter, compared to analyst estimates of $25.63 million. During the same period in the previous year, the company earned ($0.16) earnings per share. The company's quarterly revenue was down 31.4% compared to the same quarter last year.  RxSight has set its FY 2025 guidance at  EPS. As a group, analysts anticipate that  RxSight, Inc. will post -0.7 earnings per share for the current year. </p><h2>Analysts Set New Price Targets</h2><p>Several equities analysts have commented on RXST shares. Zacks Research raised shares of RxSight from a &#34;strong sell&#34; rating to a &#34;hold&#34; rating in a research report on Monday, September 8th. Wall Street Zen lowered RxSight from a &#34;hold&#34; rating to a &#34;sell&#34; rating in a report on Saturday, July 12th. JPMorgan Chase &amp; Co. boosted their target price on RxSight from $8.00 to $9.00 and gave the stock an &#34;underweight&#34; rating in a report on Thursday. UBS Group lowered their price target on RxSight from $16.00 to $8.00 and set a &#34;neutral&#34; rating on the stock in a report on Friday, August 8th. Finally, Jefferies Financial Group  restated a &#34;hold&#34; rating and issued a $9.00 price objective (down from $24.00) on shares of RxSight in a research note on Thursday, July 10th. One equities research analyst  has rated the stock with a Buy rating, nine have issued  a Hold rating and three have given a Sell rating to the company's stock. Based on data from MarketBeat.com, the stock  has a consensus rating of &#34;Reduce&#34; and an average target price of $9.56.</p><p><b>Read Our Latest Research Report on RxSight</b></p><h2>About RxSight</h2> (Free Report)<p>RxSight, Inc, a commercial-stage medical device company, engages in the research and development, manufacture, and sale of light adjustable intraocular lenses (LAL) used in cataract surgery in the United States and internationally. It offers RxSight system that enables doctors to customize and enhance the visual acuity for patients after cataract surgery.</p><h2>Featured Articles</h2><ul><li>Five stocks we like better than RxSight</li><li>How to Use the MarketBeat Stock Screener </li><li>CAVA Stock Looking for Direction After Earnings Miss</li><li>Most Volatile Stocks, What Investors Need to Know</li><li>3 Small AI Stocks Ready to Explode (All Under $20)</li><li>Insider Selling Explained: Can it Inform Your Investing Choices?</li><li>After 16% Fall, Analysts Eye a Big Recovery in Meta Platforms</li></ul><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9UlhTVA?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" width="650" height="350" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9UlhTVA"/></p><p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.</em></p><h2>Should You Invest $1,000 in RxSight Right Now?</h2><p>Before you consider RxSight, you'll want to hear this.</p><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and RxSight wasn't on the list.</p><p>While RxSight currently has a Reduce rating among analysts, top-rated analysts believe these five stocks are better buys.</p><p>View The Five Stocks Here</p>                  </div>

RXST

<p>Carnegie Lake Advisors LLC acquired 107,000 shares of RxSight, Inc. (NASDAQ:RXST) valued at approximately $1.39 million, representing about 0.26% ownership. Other institutional investors have also adjusted their stakes in the company. RxSight's stock rose 3.2% to $8.61, with a market cap of $352.32 million. The company reported a quarterly EPS of ($0.04), exceeding estimates, but revenue declined 31.4% year-over-year. Analysts have mixed ratings on the stock, with a consensus target price of $9.56.</p>

107,000 Shares in RxSight, Inc. $RXST Bought by Carnegie Lake Advisors LLC